AVISE® SLE Prognostic is a 10-marker panel developed to help assess a patient’s potential risk for Thrombosis, Cardiovascular events, Lupus Nephritis and Neuropsychiatric Lupus.

AVISE® SLE prognostic can help assess a patient’s risk of SLE associated organ involvement & thrombosis and can be ordered along with the AVISE Lupus or AVISE CTD tests.



SLE patients with positive anti-c1q levels are 2x more likely to have renal involvment.

2. Akhter E, et al. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011.

To learn more about the clinical utility of AVISE® Prognostic from your peers or read current scientific publications, please visit our Education & Resources library.
Request more information on AVISE® testing

Pin It on Pinterest

Share This